Quintrio
Home

SERVICES-HOSPITALS

Pediatrix Medical Group, Inc.

MD

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

Last trade $31.52
Day change -$0.375 (-1.18%)
Day range $31.44 – $31.98
Volume 124,575
Market cap $2.49B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.49B
Price / earnings
16.6×
Price / book
2.93×
Price / sales
1.27×
EV / sales
1.41×
EV / EBITDA
10.53×

Profitability

Earnings per share
$1.92
Return on assets
7.02%
Return on equity
17.67%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.68×
Current ratio
1.28×
Quick ratio
1.28×
Cash ratio
0.58×

Cash flow

Price / cash flow
10.98×
Price / free cash flow
11.89×
Free cash flow
$209.59M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$501.37M$487.78M$476.2M$493.77M$492.88M$468.84M$458.36M$502.36M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$501.37M$487.78M$476.2M$493.77M$492.88M$468.84M$458.36M$502.36M
Selling, general and administrative$62.7M$397.41M$406.01M$1.41B$60.79M$379.22M$395.64M$1.5B
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$436.16M$430.86M$434.54M$444.98M$424.82M$408.98M$426.26M$464.31M
Operating income$65.21M$56.92M$41.66M$48.79M$68.05M$59.87M$32.1M$38.06M
Interest expense-$8.13M-$8.17M-$8.27M-$8.74M-$8.94M-$9.13M-$9.15M-$9.71M
Income before taxes$64.99M$54M$38.84M$45.6M$87.78M$54.97M$28.09M$33.33M
Income taxes$18M$14.16M$9.27M$11.91M$16.07M$15.71M$7.35M$2.85M
Net income$46.99M$39.84M$29.57M$33.68M$71.71M$39.26M$20.74M$30.48M
Net income attributable to common shareholders$46.99M$39.84M$29.57M$33.68M$71.71M$39.26M$20.74M$30.48M
EBITDA$77.57M$71.18M$52.7M$60.3M$79.56M$69.01M$44.04M$64.97M
Basic earnings per share$0.61$0.50$0.37$0.41$0.85$0.46$0.25$0.37
Diluted earnings per share$0.59$0.49$0.36$0.40$0.84$0.46$0.24$0.37

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

MDT Q2 Earnings Preview: Will Cardiovascular Performance Lift Results?

Medtronic is expected to report Q2 fiscal 2027 results on November 24, with revenues projected to grow 5.7% to $9.47 billion and EPS estimated at $1.34 (down 1.5% YoY). The Cardiovascular segment is expected to drive growth at 9.6%, supported by cardiac ablation, CRM, and structural heart products. Diabetes revenues are projected to grow 12.9% following the MiniMed separation. However, the company has a negative Earnings ESP of -0.75%, suggesting limited upside surprise potential.

Zacks Investment Research

What Makes Pediatrix Medical Group (MD) a Strong Momentum Stock: Buy Now?

Pediatrix Medical Group (MD) is highlighted as a momentum stock with a Zacks Rank #2 (Buy) rating and Momentum Style Score of B. The stock has shown strong recent performance, up 4.93% over the past week, 16.98% monthly, 19.55% quarterly, and 39.52% over the past year, outperforming the S&P 500. Earnings estimate revisions have been positive, with 2 upward revisions in the past two months for both current and next fiscal year, supporting the bullish outlook.

Zacks Investment Research

Pediatrix Medical Group (MD) Upgraded to Buy: Here's What You Should Know

Pediatrix Medical Group has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates. The upgrade reflects positive sentiment about the company's earnings outlook, with analysts raising consensus estimates by 3.4% over the past three months. The company is expected to earn $2.37 per share for fiscal year 2026.

Zacks Investment Research

Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock

Zacks presents its investment research tools including Thematic Investment Screens covering 37 themes and Style Scores that complement the Zacks Rank system. The article explains how combining the Zacks Rank with Style Scores (Value, Growth, Momentum, and VGM) helps investors identify stocks with the highest probability of outperformance. Pediatrix Medical Group (MD) is highlighted as a #2 Buy with strong momentum metrics.

Zacks Investment Research

Pediatrix Medical Group (MD) Beats Q3 Earnings and Revenue Estimates

Pediatrix Medical Group reported Q3 2026 earnings of $0.72 per share, beating consensus estimates of $0.63 and surpassing revenue expectations. The company has outperformed the S&P 500 by 35.2% year-to-date. However, it received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, with the Medical Services industry ranking in the bottom 40% of sectors.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 20, 20132-for-1forward split
Apr 28, 20062-for-1forward split